Current Atherosclerosis Reports

, Volume 11, Issue 1, pp 15–22 | Cite as

Is a statin as part of a polypill the answer?

Article

Abstract

Statins are a necessary component of a polypill. Almost all patients have the potential to benefit from low-density lipoprotein cholesterol reduction with statins, although absolute benefits due to the reduction in coronary heart disease and stroke vary by risk level. The reduction in coronary heart disease and stroke from antihypertensive therapy is additive to the reduction in risk from statins. Used in combination with antihypertensive therapy, a moderate-dose statin would be expected to reduce cardiovascular risk by at least 50%, and a high-dose statin would be expected to reduce risk by at least 60% over an approximately 5-year period. A polypill containing aspirin in addition to a statin and antihypertensive therapy would be appropriate for most men over age 55 years, but not for high-risk women until age 65 years and moderately high-risk women until age 75 years. Polypills in development hold great promise for reducing the global burden of cardiovascular disease.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Wald NJ, Law MR: A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003, 326:1419–1424.PubMedCrossRefGoogle Scholar
  2. 2.
    Lim SS, Gaziano TA, Gakidou E, et al.: Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet 2007, 370:2054–2062.PubMedCrossRefGoogle Scholar
  3. 3.
    Davidson MH, Robinson JG: Lipid-lowering effects of statins: a comparative review. Exp Opin Pharmacother 2006, 7:1701–1714.CrossRefGoogle Scholar
  4. 4.
    Robinson JG, Smith B, Maheshwari N, Schrott H: Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005, 46:1855–1862.PubMedCrossRefGoogle Scholar
  5. 5.
    Cholesterol Treatment Trialists’ (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267–1278.CrossRefGoogle Scholar
  6. 6.
    Cannon CP, Steinberg BA, Murphy SA, et al.: Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006, 48:438–445.PubMedCrossRefGoogle Scholar
  7. 7.
    Pfizer Inc.: Lipitor (atorvastatin calcium) [prescribing information]. Available at: http://www.pfizer.com/files/products/uspi_lipitor.pdf. Accessed on June 7, 2008.
  8. 8.
    Merck & Co.: Mevacor (lovastatin) [prescribing information]. Available at: http://www.merck.com/product/usa/pi_circulars/m/mevacor/mevacor_pi.pdf. Accessed on July 1, 2008.
  9. 9.
    Merck & Co.: Zocor (simvastatin) [prescribing information]. Available at: http://www.merck.com/product/usa/pi_circulars/z/zocor/zocor_pi.pdf Accessed on June 7, 2008.
  10. 10.
    Rubins H, Robins S, Collins D, et al.: Distribution of lipids in 8,500 men with coronary artery disease. Am J Cardiol 1995, 75:1196–1201.PubMedCrossRefGoogle Scholar
  11. 11.
    Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003, 289:2560–2571.PubMedCrossRefGoogle Scholar
  12. 12.
    Smith JS, Allen J, Blair SN, et al.: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006, 47:2130–2139.PubMedCrossRefGoogle Scholar
  13. 13.
    Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227–239.PubMedCrossRefGoogle Scholar
  14. 14.
    Beckett NS, Peters R, Fletcher AE, et al.: Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008, 358:1887–1898.PubMedCrossRefGoogle Scholar
  15. 15.
    National Cholesterol Education Panel: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002, 106:3143–3421.Google Scholar
  16. 16.
    Robinson JG, Bakris G, Torner J, et al.: Is it time for a cardiovascular primary prevention trial in the elderly? Stroke 2007, 38:441–450.PubMedCrossRefGoogle Scholar
  17. 17.
    Afilalo J, Duque G, Steele R, et al.: Statins for secondary prevention in elderly patients: a hierarchical Bayesian metaanalysis. J Am Coll Cardiol 2004, 51:37–45.CrossRefGoogle Scholar
  18. 18.
    Julius S, Nesbitt SD, Egan BM, et al.; Trial of Preventing Hypertension (TROPHY) Study Investigators: Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006, 354:1685–1697.PubMedCrossRefGoogle Scholar
  19. 19.
    D’Agostino RB Sr, Vasan RS, Pencina MJ, et al.: General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008, 117:743–753.PubMedCrossRefGoogle Scholar
  20. 20.
    Sever P, Dahlof B, Poulter N, et al.: Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006, 27:2982–2988.PubMedCrossRefGoogle Scholar
  21. 21.
    Goldstein LB, Amarenco P, Szarek M, et al.: Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2007, 70:2364–2370.PubMedCrossRefGoogle Scholar
  22. 22.
    Berger JS, Roncaglioni MC, Avanzini F, et al.: Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006, 295:306–313.PubMedCrossRefGoogle Scholar
  23. 23.
    Greving JP, Buskens E, Koffijberg H, Algra A: Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation 2008, 117:2875–2883.PubMedCrossRefGoogle Scholar
  24. 24.
    Robinson JG, Maheshwari N: A “poly-portfolio” for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years. Am J Cardiol 2005, 95:373–378.PubMedCrossRefGoogle Scholar
  25. 25.
    LaRosa JC, Grundy SM, Waters DD, et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425–1435.PubMedCrossRefGoogle Scholar
  26. 26.
    LaRosa JC, Grundy SM, Kastelein JJ, et al.; Treating to New Targets (TNT) Steering Committee and Investigators: Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the Treating to New Targets [TNT] study). Am J Cardiol 2007, 100:747–752.PubMedCrossRefGoogle Scholar
  27. 27.
    AstraZeneca Pharmaceuticals: Crestor (rosuvstatin calcium) [prescribing information]. Available at http://www.astrazeneca-us.com/pi/crestor.pdf. Accessed on February 10, 2007.
  28. 28.
    Robinson J, Davidson M: Combination therapy with ezetimibe and simvastatin to acheive aggressive LDL reduction. Expert Rev Cardiovasc Ther 2006, 4:461–476.PubMedCrossRefGoogle Scholar
  29. 29.
    McKenney JM, Jones PH, Bays HE, et al.: Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 2007, 192:432–437.PubMedCrossRefGoogle Scholar
  30. 30.
    Davidson M, Robinson JG: Safety of aggressive lipid management. J Am Coll Cardiol 2007, 49:1753–1762.PubMedCrossRefGoogle Scholar
  31. 31.
    Robinson JG, Stone NJ: Identifying patients for aggressive cholesterol lowering: The risk curve concept. Am J Cardiol 2006, 98:1405–1408.PubMedCrossRefGoogle Scholar
  32. 32.
    Law MR, Wald NJ, Morris J: Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assessment 2003, 7:1–108.Google Scholar
  33. 33.
    Tsivgoulis G, Spengos K, Karandreas N, et al.: Presymptomatic neuromuscular disorders disclosed following statin treatment. Arch Intern Med 2006, 166:1519–1524.PubMedCrossRefGoogle Scholar
  34. 34.
    Silva M, Matthews ML, Jarvis C, et al.: Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther 2007, 29:253–260.PubMedCrossRefGoogle Scholar
  35. 35.
    Davidson M, Clark J, Glass L, Kanumalla A: Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol 2006, 97(Suppl 1):32C–43C.PubMedCrossRefGoogle Scholar
  36. 36.
    Law MR, Wald NJ, Morris JK, Jordan RE: Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003, 326:1427–1431.PubMedCrossRefGoogle Scholar
  37. 37.
    Bangalore S, Kamalakkannan G, Parkar S, Messerli FH: Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007, 120:713–719.PubMedCrossRefGoogle Scholar
  38. 38.
    Choudhry NK, Avorn J, Antman EM, et al.: Should patients receive secondary prevention medications for free after a myocardial infarction? An economic analysis. Health Affairs 2007, 26:186–194.PubMedCrossRefGoogle Scholar
  39. 39.
    Nainggolan L: Clinical trials of polypills for CVD begin. Available at: http://www.medscape.com/viewarticle/551002. Accessed on June 13, 2008.
  40. 40.
    World Heart Federation: Polypill reaches clinical testing phase [press release]. Available at: http://www.worldheart.org/press/press-releases/news-details/article/polypillreaches-clinical-testing-phase-1/. Accessed on July 1, 2008.
  41. 41.
    Stiles S: Polypill progress: clinical testing imminent for three-agent secondary-prevention pill. Available at: http://www.theheart.org/article/868981.do. Accessed on July 1, 2008.
  42. 42.
    Templeton S: Over 55s to get life-saving polypill. Sunday-Times. May 4, 2008.Google Scholar
  43. 43.
    Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists’ Collaboration: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000, 356:1955–1964.PubMedCrossRefGoogle Scholar
  44. 44.
    Population Division, U.S. Census Bureau: Table 1: Annual Estimates of the Population by Sex and Five-Year Age Groups for the United States: April 1, 2000 to July 1, 2007 (NC-EST2007-01); May 1, 2008.Google Scholar
  45. 45.
    Fedder DO, Koro CE, L’Italien GJ: New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation 2002, 105:152–156.PubMedCrossRefGoogle Scholar
  46. 46.
    Ostchega Y, Dillon CF, Hughes JP, et al.: Trends in hypertension prevalence, awareness, treatment, and control in older U.S. adults: data from the National Health and Nutrition Examination Survey 1988 to 2004. J Am Geriatr Soc 2007, 55:1056–1065.PubMedCrossRefGoogle Scholar
  47. 47.
    Ong KL, Cheung BM, Man YB, et al.: Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension 2007, 49:69–75.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2009

Authors and Affiliations

  1. 1.Departments of Epidemiology & Medicine, Lipid Research ClinicUniversity of IowaIowa CityUSA

Personalised recommendations